To determine whether KDM5B can repress immune target genes in urothelial cancer, we used the KDM5-inhibitor (KDM5i) C7034,35 in S1-like RT4 bladder cancer cells, which harbor an oncogenic FGFR3-TACC3 fusion36. This evidence concerns the gene FGFR3 and urinary bladder cancer.